New England-based CRO Agilux Laboratories, a provider of drug metabolism and pharmacokinetics (DMPK) services to sponsors, has expanded its in vivo pharmacokinetics services to support clients' demands and increased service requirements. The space expansion will allow Agilux to significantly increase its capacity and volume, while maintaining fast study starts.

Agilux has more than doubled its dedicated vivarium space, which enables an increase in all in vivo services with potential for additional species and genders. Agilux immediately is able to utilize 50% of the new space, with additional capacity available to its client base.